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Summary
Objective: To determine whether the focal susceptibility to cartilage degeneration in joints is related to a differential response to cytokine
stimulation.
Methods: Compare aggrecan and collagen catabolism in in-vitro models of cartilage degradation induced by retinoic acid (RA), interleukin-1
(IL-1), tumor necrosis factor alpha (TNF) and IL-1 plus oncostatin M (OSM). Glycosaminoglycan (GAG) and hydroxyproline (HyPro)
quantiﬁcation and Western immunoblot analyses of aggrecan and collagen degradation products were undertaken in explant cultures of
normal cartilage from regions of equine joints with a known high and low susceptibility to degeneration in disease. RNA isolation and semi
quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis were performed to determine the expression of
aggrecanases, matrix metalloproteinases (MMPs) and their inhibitors.
Results: Although the rate of basal cartilage aggrecan turnover was dependent on joint region there was no difference in the response of
different cartilages to cytokines. Individual animals did show a signiﬁcant difference in the response of certain cartilages to cytokines, with both
decreased and increased aggrecan loss in cartilage with a low susceptibility to degeneration. Aggrecan release in both short- and long-term
cultures from all cartilages was associated with increased cleavage by aggrecanases rather than MMPs. There was a poor correlation
between expression of aggrecanases, MMPs or their inhibitors and cytokine induced aggrecan catabolism. IL-1 alone was able to stimulate
collagen breakdown in equine articular cartilage and surprisingly, signiﬁcantly more collagen loss was induced in cartilage from regions less
susceptible to degeneration.
Conclusions: Collectively, these studies suggest that a regional difference in response to catabolic cytokines is unlikely to be a factor in the
initiation of focal cartilage degeneration in osteoarthritis (OA).
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Articular cartilage degeneration and erosion are hallmarks
of both degenerative and inﬂammatory joint diseases. In the
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Received 30 June 2004; revision accepted 22 October 2004.16inﬂammatory arthritides, it is well accepted that cytokines
such as interleukin-1 (IL-1) and tumour necrosis factor
alpha (TNF) are key mediators of the disease pathophys-
iology. There is extensive evidence from in vitro studies,
that both IL-1 and TNF can stimulate the synthesis and
activation of proteolytic enzymes by chondrocytes, resulting
in the catabolism of the principal extracellular matrix
components of cartilage, aggrecan and type II collagen
(reviewed in Ref.1). Although similar proteolytic events
occur in the cartilage of both the degenerative arthropathies
such as osteoarthritis (OA) and the inﬂammatory diseases
such as rheumatoid arthritis, the role of inﬂammatory
cytokines in OA is less clear. IL-1 and TNF have been
detected in OA synovial ﬂuid but the levels are lower than
those in rheumatoid arthritis2e4. Nevertheless, synovium
from OA joints does secrete signiﬁcantly more TNF and IL-12
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chondrocytes in the superﬁcial zones of OA cartilage are
immuno-positive for these two cytokines6. Finally, chon-
drocytes from OA cartilage express more p55 TNF receptor
and type I IL-1 receptor than cells from normal cartilage and
as a consequence are more responsive to these catabolic
cytokines7e9.
Despite the evidence implicating catabolic cytokines in
the pathogenesis of OA, it is difﬁcult to reconcile with the
distinct topographical distribution of cartilage degeneration.
The role of biomechanics in the initiation and development
of cartilage damage in OA is still the subject of investigation
and both overloading and underloading have been impli-
cated (reviewed in Ref.10). Nevertheless, the joint regions
with the most advanced cartilage lesions in late stage OA
are generally those exposed to the greatest load bearing,
such as the superolateral femoral head and the medial
femorotibial compartment11,12, implicating mechanical
rather than humoral factors in disease pathogenesis.
However, the chondrocytes from distinct joint regions have
metabolic differences that are maintained in culture
suggesting that they are phenotypically distinct cell pop-
ulations13. It has been reported that a differential response
to TNF by chondrocytes from topographically deﬁned areas
could contribute to the focal nature of cartilage degenera-
tion in OA8,14,15. In these studies pathological cartilage from
human knees was used and it is therefore unclear whether
the different response was a cause or an effect of focal
disease. The purpose of the present investigation was to
examine what role differential cytokine response might play
in the initiation of focal cartilage damage in joint disease. To
this end, we compared normal equine cartilage from deﬁned
joint regions with a known low or high susceptibility to
degeneration in disease16e18. The expression and activity
of the matrix degrading metalloproteinase enzymes and
their natural inhibitors was evaluated using in-vitro models
of cartilage degradation. Collectively, these studies have
demonstrated that the regional susceptibility of cartilage to
degeneration in arthritic diseases was not associated with
a differential response to cytokines in vitro.
Materials and methods
IN-VITRO MODELS OF CARTILAGE DEGENERATION
Full-depth articular cartilage was harvested from three
areas of horses (2e12 years of age): high degeneration
susceptibility regions of the distal metacarpus (MCP) and
the dorsal rim of the third carpal bone (DR), and the low
susceptibility palmar condyle of the third carpal bone (PC).
The variable incidence of degenerative change, biome-
chanical loading and biochemistry of the DR and PC along
with the location of these regions within the joint have been
described previously16e21. The MCP was chosen to
represent another cartilage region with a high incidence of
degeneration (load-bearing region of the medial condyle) in
a joint separate from the carpus to see if similarities existed
between susceptible cartilages in different joints22,23. All
joints were assessed visually to ensure that there was no
gross evidence of joint disease such as osteophytes or
cartilage ﬁbrillation. Histological evaluation of selected
cartilage specimens was also undertaken to ensure that
there was no evidence of proteoglycan loss, chondrocyte
cloning or surface ﬁbrillation indicative of disease. Cartilage
was pre-cultured for 3 days in Dulbecco’s Modiﬁed Eagles
Medium (DMEM; Gibco BRL)C 10% foetal bovine serum,
washed (3! 5 min) and cultured in serum free DMEM.Cartilage degradation models characterised by aggrecan
loss but little or no collagen catabolism, were established
using 4 day serum free cultures G106 M retinoic acid
(RA), 10 ng/ml IL-1 beta or 100 ng/ml TNF alpha24. To try
and model cartilage degeneration characterised by type II
collagen proteolysis, long-term (up to 28 days) serum free
cultures G10 ng/ml IL-1 beta or 1 ng/ml IL-1 beta plus
50 ng/ml OSM with media changed every 7 days were
established25. Quadruplicate samples from each joint
region of individual horses were cultured and the cartilage
and media were harvested after 4 days (short-term culture)
or 7, 14, 21 and 28 days (long-term culture). At the
termination of culture, medium was frozen at 20(C until
analysed and cartilage was blotted dry, weighed and
extracted for 48 h at 4(C using 10 volumes of 4 M
guanidinium hydrochloride (GuHCl), 0.05 M sodium acetate
pH 6.8 containing the proteinase inhibitors 0.01 M EDTA,
0.1 M 6-aminohexanoic acid, 0.005 M benzamidine HCl and
0.01 M N-ethylmaleimide. Extracts were dialysed for 16 h
against 400 volumes of ultra-pure deionised water at 4(C
and stored at 20(C until analysed further. The cartilage
remaining after extraction was digested with papain26.
QUANTITATION OF PROTEOGLYCAN
AND COLLAGEN CATABOLISM
The proteoglycan content in the medium, dialysed
cartilage extracts and papain digests was measured as
sulphated glycosaminoglycan (GAG) by colorimetric assay
using dimethylmethylene blue (DMMB) and chondroitin
sulphate-C from shark cartilage (Sigma) as a standard27.
Collagen in the medium, extracts and papain digests was
measured as hydroxyproline (HyPro) content28. Data were
normalised by log transformation and differences in GAG or
HyPro release in association with the catabolic agent used
and joint region were studied by analysis of variance
(ANOVA) and Bonferroni Dunn post hoc analysis. Data
were analysed using the Stat View 4.02 package for
Macintosh (Abacus Concepts Inc., Berkley, CA) with
P! 0.05 being considered signiﬁcant.
SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE)
AND WESTERN BLOTTING
Proteoglycan and collagen metabolites in the conditioned
medium or cartilage extracts were electrophoretically
separated as described previously24. Brieﬂy, chondroitin
sulphate and keratan sulphate were removed by 2e4 h
digestion at 37(C with proteinase free chondroitinase ABC
(Sigma), keratanase (Seikagaku) and keratanase II (Seika-
gaku), dialysed against ultra-pure deionised water, lyophi-
lised, separated under reducing conditions on 4e12%
gradient (Novex, Frankfurt, Germany) or 10% Tris/glycine
SDS-PAGE gels and transferred to nitrocellulose mem-
branes. Loading of samples onto the gels was standardised
either by loading an equal amount of GAG for analysis of
most proteoglycan epitopes24 or an equal wet weight of
tissue for aggrecan G1 domain and type II collagen
metabolites. Immunoblotting of membranes was performed
using monoclonal antibodies (MAbs) BC-3 (1:200029)
recognising the aggrecanase-generated N-terminal inter-
globular domain of the aggrecan core protein (IGD)
neoepitope ARG.; BC-14 (1:100029,30) recognising the
matrix metalloproteinase (MMP)-generated N-terminal IGD
neoepitope FFA. (equine sequence31); BC-13 (1:50024)
recognising the aggrecanase-generated C-terminal neo-
epitope .EGE; BC-4 (1:100029) recognising the
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9A4 (1:100032) recognising the collagenase generated
C-terminal type II collagen neoepitope .AEGPPGPQG.
Incubations with primary and secondary (alkaline phospha-
tase conjugated) antibodies were performed for 1 h at room
temperature and the immunoblots were incubated with
substrate for 5e15 min at room temperature to achieve
optimum colour development.
RNA EXTRACTION AND REVERSE TRANSCRIPTION-POLYMERASE
CHAIN REACTION (RT-PCR) ANALYSES
Replicate explants to those used for biochemical analysis
(short-term culture experiments only) were used for analysis
of metalloproteinase and inhibitor mRNA expression. Total
RNA was extracted from explants and isolated using
RNeasy mini-columns and reagents (Qiagen Ltd.) accord-
ing to the manufacturers protocol and eluted in sterile
water33. The RNA obtained from explants derived from
three individuals was pooled and RT-PCR was performed
using the RNA PCR kit (PerkineElmer) as previously
described33. First strand cDNA was synthesised by RT
(2 ml RNA solution/20 ml reaction volume) using MuLV
reverse transcriptase and ‘‘hot-start’’ PCR ampliﬁcation
was performed (1 ml RT-mRNA solution/50 ml reaction
volume) using oligonucleotide primers corresponding to
cDNA sequences for A Disintegrin And a Metalloproteinase
with thrombospondin repeat (ADAMTS)-4 (ACCACTTTGA-
CACAGCCATTC and ACCCCCACAGGTCCGAGAGCA;
GenBank accession number: AF368321), ADAMTS-5
(TGTGCTGTGATTGAAGACGAT and GACTGCAG-
GAGCGGTAGATGG; GenBank accession number:
AF368322), MMP-3 (CTTTTGGCGMAAATCYCTCAG and
AAARRAACCCAAATKCTTCAA; GenBank accession
number: J03209), MMP-13 (TKCTGGCWCAYGCTTTT-
CCTC and GGTTGGGGTCTTCATCTCCTG; GenBank
accession number: NM002427), TIMP-1 (CCACCTTATAC-
CAGCGTTAT and CCTCACAGCCAACAGTGTAGG; Gen-
Bank accession number: S68252), TIMP-2 (GTGG-
ACTCTGGAAAYGACAT and TCTTCTTCTGGGTGGT-
GCTMA; GenBank accession number: S48568), TIMP-3
(GGGAAGAAGCTGGTAAAGGAG and GCCGGATGCA-
GGCGTAGTGTT; GenBank accession number:
U02571) and GAPDH (TGGTATCGTGGAAGGACTCAT
and GTGGGTGTCGCTGTTGAAGTC; GenBank acces-
sion number: X01677), where MZ A or C, YZC or T,
RZ A or G, KZG or T and WZ A or T. The PCR products
were visualised on 3% agarose gels stained with ethidium
bromide and their nucleotide sequences veriﬁed using an
ABI 310 Genetic Analyser.
Results
SHORT-TERM CARTILAGE CULTURES
There was no detectable release of HyPro in any of the
joint regions over 4 days of culture under any condition
(data not shown). Data pooled from all horses (nZ 5) on
the release of GAG into the medium (expressed as
a percentage of total) are shown in Fig. 1(A). In control
cultures more GAG was released from the high weight-
bearing carpal cartilage (DR) compared with the other
regions (P! 0.006 for both analyses). There was a signif-
icant effect of RA, IL-1 and TNF on GAG release
(P! 0.0001). RA, which was used as a positive control
to determine maximal GAG release from the differentcartilages, induced a signiﬁcantly greater release than
either IL-1 or TNF (P! 0.0006). There was no difference
between the three regions in their response to any of the
catabolic stimuli (expressed either as % of total or as
a percentage of the mean control value). When the data
from individual horses were analysed separately, one
animal showed signiﬁcantly less response to catabolic
stimulation in the PC cartilage [Fig. 1(B), Horse 1;
P! 0.0001], while in a second animal cartilage from the
PC was signiﬁcantly more responsive [Fig. 1(B), Horse 2;
P! 0.0001] to all three catabolic stimuli compared with
the other regions. No correlation between the age of the
horses and the response to catabolic stimulation was
evident.
The proteinases responsible for aggrecan release were
evaluated by Western blot analyses with MAbs recognising
aggrecanase- and MMP-generated neoepitope sequences
(Fig. 2). Medium from control cultures of all horses (nZ 5)
regardless of age or joint region contained aggrecanase-
generated (BC-3 positive) aggrecan metabolites of approx-
imately 120 kDa molecular mass [Fig. 2(A)]. Cartilage from
all three regions had an increased release of BC-3 positive
metabolites with RA, IL-1 and TNF stimulation. In catabol-
ically stimulated cultures, the aggrecanase-generated
metabolites ranged in molecular mass from 60 to
O250 kDa and there was no consistent difference between
regions in the distribution of these BC-3 positive aggrecan
fragments. No MMP-generated aggrecan metabolites (BC-
14 positive) were detected in culture medium from any
region or treatment (not shown). When an equivalent
amount of equine aggrecan (20 mg GAG) was subjected
to MMP-3 digestion and Western blot analysis, numerous
BC-14 positive bands were observed [Fig. 2(B)]. As
described previously with porcine and bovine aggre-
can24,34, BC-14 was able to detect equine MMP-generated
aggrecan metabolites when 3% or more of the loaded
sample initiated with the FFA. sequence (data not shown).
Both aggrecanase- and MMP-generated G1-bearing me-
tabolites were detected in control cartilage [Fig. 2(C)].
Extracts of cartilage at the time of harvest from the joint
demonstrated that these metabolites were present prior to
the initiation of culture and no difference was found between
joint regions (data not shown). The increase in BC-3
[Fig. 2(A)] correlated with increased BC-13 reactive
metabolites in the cartilage extracts from all regions
[Fig. 2(C)]. In contrast, the levels of BC-4 remained largely
unchanged, consistent with the lack of BC-14 [Fig. 2(B)]
and results in other species24.
Analysis of the expression of mRNA for aggrecanases,
MMPs and TIMPs using RT-PCR was performed on pooled
RNA to determine whether any differences existed between
cartilages commonly (MCP and DR) or rarely (PC) affected
by arthritic degeneration (Fig. 3). The mRNA for ADAMTS-4
was not expressed in any cartilage prior to culture or in any
control or RA stimulated cartilages. Expression of
ADAMTS-4 was induced by IL-1 (MCP and DR) and TNF
(DR and PC). The mRNA for ADAMTS-5 was present in all
cartilages prior to culture but this expression was markedly
decreased or abolished in control cultures. ADAMTS-5
mRNA was induced by RA (MCP and DR), IL-1 (MCP) and
TNF (DR and PC). mRNA for MMP-3 and -13 was detected
in MCP but not other cartilages prior to culture. When
compared with control cultures, IL-1 and TNF induced
expression of MMP-3 and -13 in all cartilages. Message for
TIMPs-1, -2 and -3 was present prior to culture in cartilage
from all regions. TIMP-1 message was unaffected by any
culture condition. In contrast, TIMP-2 mRNA was generally
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Fig. 1. Effect of culture on glycosaminoglycan (GAG) release (% of total) into the culture medium from equine articular cartilage. Normal
cartilage from joint regions with high (the distal metacarpus (MCP) and dorsal rim if the third carpal bone (DR)) and low susceptibility to disease
(palmar condyle of the third carpal bone (PC)) was cultured for 4 days in the absence of any catabolic stimulation (C) or in the presence of
106 M retinoic acid (RA), 10 ng/ml interleukin-1 beta (IL-1) or 100 ng/ml tumor necrosis factor alpha (TNF). Pooled data from all horses (A,
nZ 5) and two individual animals (B) are presented. *Z Signiﬁcantly different (P! 0.05) release when compared to other cartilage region
cultures under the same conditions.diminished in all cultured cartilages, particularly by TNF.
TIMP-3 mRNA expression was still detected in most
cultured cartilage although it was generally down regulated
by TNF treatment in all three regions.
LONG-TERM CARTILAGE CULTURES
IL-1 and IL-1/OSM signiﬁcantly increased GAG release
from cartilage when compared with controls [Fig. 4(A);
P! 0.0001], with 60e80% of total cartilage GAG being
released during the ﬁrst 7 days of culture. There was
a signiﬁcantly greater release of GAG induced by IL-1/OSM
compared with IL-1 alone during days 0e7 (PZ 0.03).
There was no difference between joint regions in GAG
release on any day when pooled or when individual animal
data (results not shown) were analysed. Treatment with IL-1
but not IL-1/OSM signiﬁcantly increased HyPro release
from both DR and PC cartilage [Fig. 4(B); P! 0.0001].
Approximately 30% of the total cartilage HyPro was
released from both cartilages over the 4 weeks of culture
in the presence of IL-1. The IL-1/OSM increase in HyPro
release from both PC and DR cartilage during days 22e28
[Fig. 4(B)], failed to reach statistical signiﬁcance. There wasa difference between PC and DR cartilage HyPro release
during days 8e14 of culture (PZ 0.001), with PC cartilage
releasing signiﬁcantly more HyPro in response to IL-1
stimulation at this time.
In order to determine whether the release of GAG and
HyPro from the DR and PC cartilages was due to similar
proteolytic events, and whether this differed between
catabolic stimuli or time in culture, Western blot analysis
of the aggrecan and type II collagen metabolites released
into the culture media was performed. No differences in
Western blot analysis between the DR and PC cartilages
were detected at any time point, so for simplicity blots
representative of both cartilages are shown in Fig. 5(A,B).
Throughout the 4 weeks, both IL-1 and IL-1/OSM increased
aggrecanase-mediated cleavage of aggrecan compared
with controls, as shown by the BC-3 Western blot analysis
[Fig. 5(A)]. There was a decrease in the molecular mass of
the BC-3 positive metabolites with time. Most notably,
a novel band of BC-3 positive metabolites between 75 and
100 kDa molecular mass became apparent in IL-1 treated
cultures during days 15e21 and 22e28 and also in IL-1/
OSM treated cultures in days 22e28 [Fig. 5(A)]. No BC-14
positive metabolites were detected in media from any
cultures at any time (data not shown). Collagen catabolism
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Fig. 2. Western blot analysis of aggrecan degradation products in
the medium (A) or cartilage extracts (C) of equine articular cartilage
cultures. Normal cartilage from joint regions with high (the distal
metacarpus (MCP) and dorsal rim if the third carpal bone (DR)) and
low susceptibility to disease (palmar condyle of the third carpal
bone (PC)) was cultured for 4 days in the absence of any catabolic
stimulation (C) or in the presence of 106 M retinoic acid (RA),
10 ng/ml interleukin-1 beta (IL-1) or 100 ng/ml tumor necrosis factor
alpha (TNF). (A) Aggrecanase-generated aggrecan catabolites
initiating with the neoepitope sequence ARG. released into the
medium were detected with monoclonal antibody BC-3. (B)
Aggrecan fragments with the FFA. N-terminal neoepitope result-
ing from MMP-3 cleavage of equine aggrecan were detected with
monoclonal antibody BC-14. (C) Aggrecan metabolites with the C-
terminal neoepitope sequence .EGE and .PEN resulting from
aggrecanase and MMP cleavage of aggrecan were detected with
monoclonal antibodies BC-13 and BC-4, respectively. The migra-
tion position of pre-stained globular protein standards is shown on
the left of each blot.was associated with an increase in detection of collage-
nase-generated neoepitopes in both the GuHCl extracts
(not shown) and culture medium [Fig. 5(B)]. The 9A4
positive metabolites were of multiple molecular weights
consistent with secondary N-terminal catabolism of the
collagenase-generated 3/4 fragment.
Discussion
In joint diseases such as OA, cartilage damage is not
uniform across the joint surface, rather it occurs in well-
deﬁned regions. Recent evidence has implicated variability
in responsiveness of chondrocytes to catabolic cytokines, in
the focal distribution of cartilage degeneration in human
OA8,14,15. In the present investigation we could not
demonstrate a signiﬁcant difference in RA, IL-1, TNF or
IL-1/OSM stimulated proteoglycan catabolism in equine
cartilage from joint regions with a low vs high incidence of
susceptibility to arthritic degeneration. In the previous work,
much lower doses of catabolic cytokines were used8,14,15.
With the high cytokine doses used in the present study we
did nevertheless demonstrate signiﬁcant differences be-
tween cartilage regions in certain individuals [Fig. 1(B)].
However, even in these two animals, the differences were
not consistent with one showing increased and one
decreased catabolism in the low susceptibility region
(PC). While species differences could account for the
divergent results of the present and previous reports, it
seems more likely that the disease state of the joints from
which the cartilage was obtained is responsible for the
disparity. In the present study all joints were free from
disease while the previous investigations used cartilage
from late stage OA joints at the time of replacement surgery.
Taken together these results suggest that differential
response to cytokine stimulation is a result rather than
a cause of focal cartilage degeneration.
Consistent with other species (reviewed in Ref.1),
aggrecan loss from equine articular cartilage was associ-
ated with increased cleavage by aggrecanases and not
MMPs. There was no evidence for a difference in the
proteolytic mechanisms involved in cartilage aggrecan
release either from different joint regions or in response to
different catabolic stimuli. In contrast to normal cartilage
from other species, aggrecanase-generated metabolites
were readily detected in medium from control cultures of all
equine cartilages regardless of the age of the animal at
levels similar to those previously demonstrated in OA
human cartilage24,35,36. This suggests that articular carti-
lage in normal equine joints has a higher basal aggreca-
nase activity, which could render it more susceptible to
degeneration. ADAMTS-5 but not -4 was expressed in all
equine cartilages at the time of collection from the joint. This
ﬁnding is consistent with data suggesting that ADAMTS-5 is
constitutively expressed and as such may be the aggreca-
nase responsible for basal aggrecan turnover in carti-
lage36e39. While expression of ADAMTS-5 was markedly
decreased in control cultures when compared with ex vivo
cartilage, it was still detected in the high weight-bearing DR
cartilage (Fig. 3), which also had a higher basal release of
GAG [Fig. 1(A)]. This ﬁnding is again consistent with the
suggested role of ADAMTS-5 in normal/basal aggrecan
turnover. Expression of ADAMTS-5 was increased, albeit
inconsistently, by culturing with RA, IL-1 or TNF, indicating
that similar regulation of this gene could occur in vivo.
Unchanged, decreased and increased ADAMTS-5 expres-
sion have all been reported in human OA compared with
normal cartilage36,38,39.
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Fig. 3. Effect of culture on mRNA expression of metalloproteinases and their inhibitors in equine cartilage from different joint regions. Normal
cartilage from joint regions with high (the distal metacarpus (MCP) and dorsal rim if the third carpal bone (DR)) and low susceptibility to disease
(palmar condyle of the third carpal bone (PC)) was analysed immediately after harvest from the joint (direct extracts) or after culture for 4 days
in the absence of any catabolic stimulation (C) or in the presence of 106 M retinoic acid (RA), 10 ng/ml interleukin-1 beta (IL-1) or 100 ng/ml
tumor necrosis factor alpha (TNF). Cartilage from three horses was pooled and RT-PCR was performed using primers speciﬁc for a number of
metalloproteinases and their inhibitors.ADAMTS-4 message was not detected prior to culture in
these normal equine cartilages but was stimulated by IL-1
and TNF but not RA. The pattern of ADAMTS-4 and -5
mRNA regulation by catabolic agents was not consistent
and did not appear to correlate with cartilage regions with
high vs low incidence of disease. There are a number of
possible explanations for cartilage cultures where, despite
evidence of increased aggrecanase activity, no mRNA for
either ADAMTS-4 or -5 could be detected (e.g., TNF
stimulated MCP or RA stimulated PC). Up-regulation of
ADAMTS-4 and -5 expression may only occur during the
initial 24 h after stimulation and then decline40. Aggreca-
nases other than ADAMTS-4 or -5 may be responsible for
aggrecan catabolism in these culture systems or the
regulation of activity may not be primarily at the level of
transcription. Recent evidence indicates that ADAMTS-4
activity may be controlled through C-terminal proteolysis of
the secreted enzyme41. Finally, the level of natural inhibitorsof ADAMTS, such as TIMP-342, may modulate enzyme
activity. The expression of both MMP-3 and -13 in MCP but
not other cartilages prior to culture did not appear to be
related with increased basal matrix turnover in this joint
region. The metacarpophalangeal joint has a high incidence
of disease23, however there was no evidence grossly or
histologically (not shown) for pathological change. Although
this does not rule out the possibility that the MCP cartilage
used in this study had early degenerative change, the fact
that the basal GAG release was not elevated and there was
no difference in cytokine response argues against this.
Further investigation of the signiﬁcance and consequences
of MMP-3 and -13 expression in MCP cartilage in vivo is
required. While both MMPs were expressed in control
cultures of DR cartilage, the higher basal aggrecan turnover
in this region was not associated with detectable MMP
cleavage. Increased expression of both MMPs in response
to IL-1 and TNF stimulation did not differ between regions,
168 C. B. Little et al.: Cytokines in focal cartilage breakdownand again was not associated with detectable proteolysis of
aggrecan or collagen in these short-term cultures.
It is well recognised that MMP activity is tightly controlled
post-transcriptionally and that activation of latent enzyme is
responsible for regulating collagenolysis in explant cul-
tures43. Normal equine articular cartilage differed from other
species in that IL-1 alone rather than IL-1 plus OSM,
induced signiﬁcant collagenolysis despite the fact that OSM
did augment aggrecan release from cartilage as ex-
pected44,45. The earlier increase in collagen catabolism in
PC cartilage conﬂicts with the lower incidence of cartilage
pathology in this joint region. This ﬁnding argues strongly
against regional cytokine responsiveness being responsible
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Fig. 4. Effect of long-term culture on the release of proteoglycan
and collagen from equine articular cartilage. Normal cartilage from
joint regions with high (dorsal rim of the third carpal bone (DR)) and
low susceptibility to disease (palmar condyle of the third carpal
bone (PC)) was cultured for 7e28 days in the absence of any
catabolic stimulation (Control) or in the presence of 10 ng/ml
interleukin-1 beta (IL-1) or 1 ng/ml IL-1 plus 50 ng/ml oncostatin M
(IL-1/OSM). Release into the media of (A) glycosaminoglycan
(GAG) and (B) hydroxyproline (HyPro) was quantiﬁed as mg/mg wet
weight of cartilage.for the focal nature of cartilage degeneration observed in
OA. The collagen release in equine cartilage was due to
MMP-cleavage and increased generation of 9A4 neo-
epitope as expected46. This increase in MMP activity, while
not resulting in aggrecan IGD cleavage, was correlated with
a change in the distribution of aggrecanase-generated (BC-
3 positive) aggrecan catabolites released from the cartilage.
We have previously observed a similar phenomenon using
bovine nasal cartilage cultures46. While it is unclear whether
this C-terminal MMP-cleavage occurs before or after
aggrecanase cleavage of the IGD, identiﬁcation of these
unique smaller molecular mass BC-3 positive catabolites
may prove to be a useful surrogate marker for MMP activity
and late stage cartilage degradation.
BC-3
250kDa
150kDa
100kDa
75kDa
50kDa
C IL
-1
IL
-1
/O
SM
C IL
-1
IL
-1
/O
SM
C IL
-1
IL
-1
/O
SM
C IL
-1
IL
-1
/O
SM
C IL
-1
IL
-1
/O
SM
C IL
-1
IL
-1
/O
SM
C IL
-1
IL
-1
/O
SM
C IL
-1
IL
-1
/O
SM
A
50kDa
0-7 days 8-14 days 15-21 days 22-28 days
0-7 days 8-14 days 15-21 days 22-28 days
75kDa
100kDa
37kDa
150kDa
250kDa
9-A-4
B
Fig. 5. Western blot analysis of aggrecan (A) and collagen (B)
degradation products in the medium of equine articular cartilage
cultures. Normal cartilage from joint regions with high (dorsal rim of
the third carpal bone (DR)) and low susceptibility to disease (palmar
condyle of the third carpal bone (PC)) was cultured for 7e28 days in
the absence of any catabolic stimulation (Control) or in the
presence of 10 ng/ml interleukin-1 beta (IL-1) or 1 ng/ml IL-1 plus
50 ng/ml oncostatin M (IL-1/OSM). (A) Aggrecanase-generated
aggrecan catabolites initiating with the neoepitope sequence
ARG. released into the medium were detected with monoclonal
antibody BC-3. (B) Collagenase-generated collagen fragments
were detected with the neoepitope speciﬁc monoclonal antibody
9A4. The migration position of pre-stained globular protein stand-
ards is shown on the left.
169Osteoarthritis and Cartilage Vol. 13, No. 2In conclusion, these studies suggest that a regional
difference in response to catabolic cytokines is unlikely to
be a factor in the initiation of focal cartilage degeneration in
OA. Nevertheless, focal differences such as the elevated
basal aggrecan turnover in high weight-bearing carpal
cartilage in normal joints may well play a role in localised
degeneration. These regional differences in basal chon-
drocyte metabolism may be related to the mechanical
loading history of the cartilage and represent a distinct
topographical cell phenotype13. Increased mechanical
loading above a physiological range induces changes in
chondrocyte metabolism and initiates cartilage degenera-
tion21. The changes induced by early degeneration may
include altered sensitivity and response to catabolic
cytokines8,14,15 that could contribute to the progression of
cartilage breakdown.
References
1. Caterson B, Flannery CR, Hughes CE, Little CB.
Mechanisms involved in cartilage proteoglycan catab-
olism. Matrix Biol 2000;19:333e44.
2. Schlaak J, Pfers I, Meyer Zum Buschenfelde K, Marker-
Hermann E. Different cytokine proﬁles in the synovial
ﬂuid of patients with osteoarthritis, rheumatoid arthritis
and seronegative spondylarthropathies. Clin Exp
Rheumatol 1996;14:155e62.
3. Partsch G, Steiner G, Leeb B, Dunky A, Broll H, Smolen
J. Highly increased levels of tumor necrosis factor-
alpha and other proinﬂammatory cytokines in psoriatic
arthritis synovial ﬂuid. J Rheumatol 1997;24:518e23.
4. Horiuchi T, Yoshida T, Koshihara Y, Sakamoto H,
Kanai H, Yamamoto S, et al. The increase of
parathyroid hormone-related peptide and cytokine
levels in synovial ﬂuid of elderly rheumatoid arthritis
and osteoarthritis. Endocr J 1999;46:643e9.
5. Elson C, Mortuza F, Perry M, Warnock M, Webb G,
Westacott C. Cytokines and focal loss of cartilage in
osteoarthritis. Br J Rheumatol 1998;37:106e7.
6. Tetlow L, Adlam D, Woolley D. Matrix metalloproteinase
and proinﬂammatory cytokine production by chondro-
cytes of human osteoarthritic cartilage: associations
with degenerative changes. Arthritis Rheum 2001;44:
585e94.
7. Westacott C, Atkins R, Dieppe P, Elson C. Tumor
necrosis factor-alpha receptor expression on chon-
drocytes isolated from human articular cartilage.
J Rheumatol 1994;21:1710e5.
8. Webb G, Westacott C, Elson C. Chondrocyte tumor
necrosis factor receptors and focal loss of cartilage in
osteoarthritis. Osteoarthritis Cartilage 1997;5:427e37.
9. Martel-Pelletier J, McCollum R, DiBattista J, Faure M,
Chin J, Fournier S, et al. The interleukin-1 receptor in
normal and osteoarthritic human articular chondro-
cytes. Identiﬁcation as the type I receptor and analysis
of binding kinetics and biologic function. Arthritis
Rheum 1992;35:530e40.
10. Herzog W, Clark A, Wu J. Resultant and local loading in
models of joint disease. Arthritis Rheum 2003;49:
239e47.
11. Grushko G, Schneiderman R, Maroudas A. Some
biochemical and biophysical parameters for the study
of the pathogenesis of osteoarthritis: a comparison
between the processes of ageing and degeneration in
human hip cartilage. Connect Tissue Res 1989;19:
149e76.12. Harman M, Markovich G, Banks S, Hodge W. Wear
patterns on tibial plateaus from varus and valgus
osteoarthritic knees. Clin Orthop 1998;352:149e58.
13. Little C, Ghosh P. Variation in proteoglycan metabolism
by articular chondrocytes in different joint regions is
determined by post-natal mechanical loading. Osteo-
arthritis Cartilage 1997;5:49e62.
14. Westacott C, Barakat A, Wood L, Perry M, Neison P,
Bisbinas I, et al. Tumor necrosis factor alpha can
contribute to focal loss of cartilage in osteoarthritis.
Osteoarthritis Cartilage 2000;8:213e21.
15. Barakat A, Elson C, Westacott C. Susceptibility to
physiological concentrations of IL-1beta varies in
cartilage at different anatomical locations on human
osteoarthritic knee joints. Osteoarthritis Cartilage
2002;10:264e9.
16. Schneider R, Bramlage L, Gabel A, Barone L, Kant-
rowitz B. Incidence, location and classiﬁcation of 371
third carpal bone fractures in 313 horses. Equine Vet J
1988;6(Suppl):33e42.
17. Bramlage L, Schneider R, Gabel A. A clinical perspec-
tive on lameness originating in the carpus. Equine Vet
J 1988;6(Suppl):12e8.
18. Palmer J, Bertone A, Litsky A. Contact area and
pressure distribution changes of the equine third
carpal bone during loading. Equine Vet J 1994;26:
197e202.
19. Palmer J, Bertone A, Malemud C, Carter B, Papay R,
Mansour J. Site-speciﬁc proteoglycan characteristics
of third carpal articular cartilage in exercised and
nonexercised horses. Am J Vet Res 1995;56:1570e6.
20. Palmer J, Bertone A, Mansour J, Carter B, Malemud C.
Biomechanical properties of third carpal articular
cartilage in exercised and nonexercised horses.
J Orthop Res 1995;13:854e60.
21. Little C, Ghosh P, Rose R. The effect of strenuous
versus moderate exercise on the metabolism of
proteoglycans in articular cartilage from different
weight-bearing regions of the equine third carpal bone.
Osteoarthritis Cartilage 1997;5:161e72.
22. Norrdin R, Kawcak C, Capwell B, McIlwraith C.
Subchondral bone failure in an equine model of
overload arthrosis. Bone 1998;22:133e9.
23. Brommer H, van Weeren P, Brama P, Barneveld A.
Quantiﬁcation and age-related distribution of articular
cartilage degeneration in the equine fetlock joint.
Equine Vet J 2003;35:697e701.
24. Little CB, Flannery C, Hughes CE, Mort JS,
Roughley PJ, Dent C, et al. Aggrecanase versus
matrix metalloproteinases in the interglobular domain
catabolism of articular cartilage aggrecan in vitro.
Biochem J 1999;344:61e8.
25. Cawston TE, Curry VA, Summers CA, Clark IM,
Riley GP, Life PF, et al. The role of oncostatin M in
animal and human connective tissue collagen
turnover and its localization within the rheumatoid
joint. Arthritis Rheum 1998;41:1760e71.
26. Collier S, Ghosh P. Evaluation of the effect of
antiarthritic drugs on the secretion of proteoglycans
by lapine chondrocytes using a novel assay pro-
cedure. Ann Rheum Dis 1989;48:372e81.
27. Farndale RW, Buttle DJ, Barret AJ. Improved quanti-
tation and discrimination of sulphated glycosamino-
glycan by use of dimethylmethylene blue. Biochim
Biophys Acta 1986;883:173e7.
28. Ellis AJ, Curry VA, Cawston TE. The prevention of
collagen breakdown in bovine nasal cartilage by
170 C. B. Little et al.: Cytokines in focal cartilage breakdownTIMP-1, TIMP-2 and a low molecular weight synthetic
inhibitor. Biochem Biophys Res Commun 1994;201:
94e101.
29. Hughes CE, Caterson B, Fosang AJ, Roughley PJ,
Mort JS. Monoclonal antibodies that speciﬁcally
recognize neoepitope sequences generated by ‘ag-
grecanase’ and matrix metalloproteinase cleavage of
aggrecan: application to catabolism in situ and in vitro.
Biochem J 1995;305:799e804.
30. Caterson B, Hughes CE, Roughley P, Mort JS.
Anabolic and catabolic markers of proteoglycan
metabolism in osteoarthritis. Acta Orthop Scand
1995;66(Suppl 266):121e4.
31. Flannery CR, Little CB, Caterson B. Molecular cloning
and sequence analysis of the aggrecan interglobular
domain from porcine, equine, bovine and ovine
cartilage: comparison of proteinase-susceptible re-
gions and sites of keratan sulfate substitution. Matrix
Biol 1998;16:507e11.
32. Otterness IG, Downs JT, Lane C, Bliven ML,
Stukenbrok H, Scampoli DN, et al. Detection of
collagenase-induced damage of collagen by 9A4,
a monoclonal C-terminal neoepitope antibody. Matrix
Biol 1999;18(4):331e41.
33. Flannery CR, Little CB, Caterson B, Hughes CE.
Effects of culture conditions and exposure to catabolic
stimulators (IL-1 and retinoic acid) on the expression
of matrix metalloproteinases (MMPs) and disintegrin
metalloproteinases (ADAMs) by articular cartilage
chondrocytes. Matrix Biol 1999;18:225e37.
34. Rees SG, Flannery CR, Little CB, Hughes CE,
Caterson B, Dent CM. Catabolism of aggrecan,
decorin and biglycan in tendon. Biochem J 2000;
350:181e8.
35. Curtis C, Rees S, Little C, Flannery C, Hughes C,
Wilson C, et al. Pathologic indicators of degradation
and inﬂammation in human osteoarthritic cartilage are
abrogated by exposure to n-3 fatty acids. Arthritis
Rheum 2002;46:1544e53.
36. Malfait A, Liu R, Ijiri K, Komiya S, Tortorella M.
Inhibition of ADAM-TS4 and ADAM-TS5 prevents
aggrecan degradation in osteoarthritic cartilage. J Biol
Chem 2002;277:22201e8.
37. Bluteau G, Gouttenoire J, Conrozier T, Mathieu P,
Vignon E, Richard M, et al. Differential gene expressionanalysis in a rabbit model of osteoarthritis induced by
anterior cruciate ligament (ACL) section. Biorheology
2002;39:247e58.
38. Bau B, Gebhard P, Haag J, Knorr T, Bartnik E, Aigner
T. Relative messenger RNA expression proﬁling of
collagenases and aggrecanases in human articular
chondrocytes in vivo and in vitro. Arthritis Rheum
2002;46:2648e57.
39. Kevorkian L, Young D, Darrah C, Donell S, Shepstone
L, Porter S, et al. Expression proﬁling of metal-
loproteinases and their inhibitors in cartilage. Arthritis
Rheum 2004;50:131e41.
40. Koshy P, Lundy C, Rowan A, Porter S, Edwards D,
Hogan A, et al. The modulation of matrix metal-
loproteinase and ADAM gene expression in human
chondrocytes by interleukin-1 and oncostatin M:
a time-course study using real-time quantitative re-
verse transcription-polymerase chain reaction. Arthritis
Rheum 2002;46:961e7.
41. Gao G, Westling J, Thompson V, Howell T, Gottschall
P, Sandy J. Activation of the proteolytic activity of
ADAMTS4 (aggrecanase-1) by C-terminal truncation.
J Biol Chem 2002;277:11034e41.
42. Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3
is a potent inhibitor of ADAM-TS4 (Aggrecanase 1)
and ADAM-TS5 (Aggrecanase 2). J Biol Chem 2001;
276:12501e4.
43. Milner J, Elliott S, Cawston T. Activation of procollage-
nases is a key control point in cartilage collagen
degradation: interaction of serine and metalloprotei-
nase pathways. Arthritis Rheum 2001;44:2084e96.
44. Cawston T, Curry V, Summers C, Clark I, Riley G,
Life P, et al. The role of oncostatin M in animal and
human connective tissue collagen turnover and its
localization within the rheumatoid joint. Arthritis
Rheum 1998;41:1760e71.
45. Kozaci LD, Buttle DJ, Hollander AP. Degradation of
type II collagen, but not proteoglycan, correlates with
matrix metalloproteinase activity in cartilage explant
cultures. Arthritis Rheum 1997;40:164e74.
46. Little C, Hughes C, Curtis C, Janusz M, Bohne R,
Wang-Weigand S, et al. Matrix metalloproteinases are
involved in C-terminal and interglobular domain
processing of cartilage aggrecan in late stage cartilage
degradation. Matrix Biol 2002;21:271e88.
